Charlotte Teunissen

Nov 4, 2024 | tradingview.com | Charlotte Teunissen

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) CRVO Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB Neflamapimod treatment previously led to significant reduction in plasma GFAP levels (p=0.015 versus placebo) and these reductions were associated with an...

Apr 29, 2024 | jamanetwork.com | Rik Ossenkoppele |Vrije Universiteit Amsterdam |Amsterdam Neuroscience |Charlotte Teunissen

Fluid Biomarker Changes After Amyloid-β–Targeting Drugs Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease Olivia Wagemann, MD; Haiyan Liu, MD; Guoqiao Wang, PhD; Xinyu Shi, MS; Tobias Bittner, PhD; Marzia A. Scelsi, PhD; Martin R. Farlow, MD; David B. Clifford, MD; Charlene Supnet-Bell, PhD; Anna M. Santacruz, BS; Andrew J. Aschenbrenner, PhD; Jason J. Hassenstab, PhD; Tammie L. S. Benzinger, MD, PhD; Brian A.

Mar 21, 2024 | thelancet.com | Charlotte Teunissen |Amsterdam Neuroscience |Vrije Universiteit Amsterdam

Research in contextNeurofilament light chain (NfL) is an established biomarker for neuronal damage, and increasing evidence supports its diagnostic and prognostic value, and/or its role in monitoring treatment response in several neurological disorders. Previous studies have reported increased NfL levels in patients with GBS compared with healthy controls, and high serum NfL levels were associated with disease severity and subtype in GBS.

Jan 8, 2024 | nature.com | Betty M. Tijms |Henne Holstege |Lisa Vermunt |Niccolò Tesi |Eugeen Vanmechelen |Frederik Barkhof | +1 more

AbstractAlzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187).

Jul 13, 2023 | thelancet.com | William Jagust |Charlotte Teunissen |Charles DeCarli

The complex pathway between amyloid β and cognition: implications for therapy - The Lancet Neurology